Drugs / Trafermin
Trafermin
also known as
KCB-1 · CAB-2001 · Fiblast · recombinant human basic fibroblast growth factor · Recombinant human basic fibroblast growth factor (2-154) · rhbFGF · Trafermina · Trafermine
Protein / enzyme biologic targets FGFR2 via activation
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00199290 | Aug 2005 → Jul 2007 | periodontitis | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT00514657 | Dec 2001 → Feb 2004 | periodontitis | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02550314 | Mar 2015 → May 2016 | tympanic membrane disorder | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | No outcome recorded |
| Phase 3 | NCT01015404 | Nov 2009 → Mar 2010 | periodontitis | Kaken Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT00734708 | Aug 2008 → Mar 2010 | alveolar periostitis, periodontitis | Kaken Pharmaceutical | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01217476 Comparator | Dec 2010 → May 2012 | ulcer of lower limbs | Olympus Biotech Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01217463 Comparator | Nov 2010 → Mar 2012 | ulcer of lower limbs | Olympus Biotech Corporation | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trafermin | “NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18; fibrin glue” NCT02550314 ↗ |
| Known as | CAB-2001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108081 ↗ |
| Known as | Fiblast | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108081 ↗ |
| Known as | KCB-1 | “Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by...” NCT01217463 ↗1“Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1)” NCT01217476 ↗ |
| Known as | recombinant human basic fibroblast growth factor | “This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis” NCT00199290 ↗ |
| Known as | Recombinant human basic fibroblast growth factor (2-154) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108081 ↗ |
| Known as | rhbFGF | “This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis” NCT00199290 ↗ |
| Known as | Trafermina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108081 ↗ |
| Known as | Trafermine | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108081 ↗ |
| Action | Activate | “Fibroblast growth factor receptor 2 agonist” CHEMBL2108081 ↗ |
| Modality | Protein / enzyme biologic | “Trafermin(recombinant human basic fibroblast growth factor: rhbFGF)” NCT00199290 ↗ |
| Route | Other | “Each patient underwent flap operation during which we administered 200 microL of the appropriate investigational drug to the bone defect.” PMID 18596969 ↗ Jul 2008 |
| Target | FGFR2 | “Fibroblast growth factor receptor 2 agonist” CHEMBL2108081 ↗ |